Vimarsana
Biggest News Aggregation in the World

Page 23 - Medication Guide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medication Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medication Guide Today - Breaking & Trending Today

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease - Vimarsana News

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for...

Merck's KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery | Region - Vimarsana News

Merck's KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery | Region

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 5, 2023--

UCB presents late-breaking posters at Child Neurology Society Meeting - Vimarsana News

UCB presents late-breaking posters at Child Neurology Society Meeting

/PRNewswire/ -- The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and...

UCB presents late-breaking posters at Child Neurology Society Meeting - Vimarsana News

UCB presents late-breaking posters at Child Neurology Society Meeting

The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and developments in child neurology. As part of this conference, UCB will present two late-breaking posters that shed...

Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US - Vimarsana News

Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US

/PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that on the two-year anniversary of its launch, it has...